Clinical trial
Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as…
NCT00362986 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00362986 |
|---|---|
| Title | Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Topical Sunscreen to Prevent Erlotinib- or Cetuximab-Induced Skin Rash [or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash] |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | sunscreen, placebo |
| Enrollment | 116 |
| Start date | Oct 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Oct 1, 2009 |
| First posted | Aug 15, 2006 |
| Last update posted | Dec 13, 2016 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: